Company record
Samm Solutions, Inc., d.b.a. BTS Research
1 FDA warning letter since 2023 and 0 recalls in the last 12 months.
Get an email the day FDA posts anything new about Samm Solutions, Inc., d.b.a. BTS Research.
Warning letters
-
DrugsSamm Solutions, Inc., d.b.a. BTS Research
Samm Solutions/BTS Research failed good laboratory practice (GLP) rules for nonclinical drug studies, FDA says.
Medium